CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor

Oncogene

Volumn 31, Issue 24, 2012, Pages 2979-2988

  Rygiel, T P ^a   Karnam, G ^a   Goverse, G ^b   Van Der Marel, A P J ^b   Greuter, M J ^b   Van Schaarenburg, R A ^a   Visser, W F ^c   Brenkman, A B ^c   Molenaar, R ^b   Hoek, R M ^d   Mebius, R E ^b   Meyaard, L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Netherlands Metabolomics Center   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anti tumor responses; CD200R; immune regulation; inhibitory receptors; skin carcinogenesis

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CD200 ANTIGEN; CD200 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER GROWTH; CANCER RESISTANCE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOLOGICAL TOLERANCE; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TH17 CELL; TUMOR CELL;

ANIMALS; ANTIGENS, CD; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNE TOLERANCE; LYMPH NODES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; PAPILLOMA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

MUS;

EID: 84862312574     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.477     Document Type: Article

References (44)

1. Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH et al. (2009). IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 183: 2475-2483.
2. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
3. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS et al. (2009). Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30: 576-587.
4. Fallarino F, Asselin-Paturel C, Vacca C, Bianchi R, Gizzi S, Fioretti MC et al. (2004). Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 173: 3748-3754. (Pubitemid 39280736)
5. Finch JS, Albino HE, Bowden GT. (1996). Quantitation of early clonal expansion of two mutant 61st codon c-Ha-ras alleles in DMBA/TPA treated mouse skin by nested PCR/RFLP. Carcinogenesis 17: 2551-2557. (Pubitemid 27037608)
6. Fouser LA, Wright JF, Dunussi-Joannopoulos K, Collins M. (2008). Th17 cytokines and their emerging roles in inflammation and autoimmunity. Immunol Rev 226: 87-102.
7. Gorczynski RM, Cattral MS, Chen Z, Hu J, Lei J, Min WP et al. (1999). An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol 163: 1654-1660. (Pubitemid 29352791)
8. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM et al. (2000). Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290: 1768-1771. (Pubitemid 32004808)
9. Koenen HJ, Smeets RL, Vink PM, van RE, Boots AM, Joosten I. (2008). Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340-2352.
10. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D et al. (2007). CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 178: 5595-5605. (Pubitemid 46674355)
11. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. (2009). Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359.
12. Malliri A, van der Kammen RA, Clark K, van der Valk M, Michiels F, Collard JG. (2002). Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417: 867-871. (Pubitemid 34670335)
13. Maniati E, Soper R, Hagemann T. (2010). Up for mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653-5662.
14. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S et al. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798.
15. McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI et al. (2006). Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 103: 1041-1046. (Pubitemid 43212218)
16. Meyer KC, Klatte JE, Dinh HV, Harries MJ, Reithmayer K, Meyer W et al. (2008). Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol 159: 1077-1085.
17. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, Yang J et al. (2003). Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 170: 1304-1312. (Pubitemid 36139497)
18. Molenaar R, Greuter M, van der Marel AP, Roozendaal R, Martin SF, Edele F et al. (2009). Lymph node stromal cells support dendritic cell-induced gut-homing of T cells. J Immunol 183: 6395-6402.
19. Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E et al. (2006). CD200 is a new prognostic factor in multiple myeloma. Blood 108: 4194-4197. (Pubitemid 44913292)
20. Mukhopadhyay S, Pluddemann A, Hoe JC, Williams KJ, Varin A, Makepeace K et al. (2010). Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia. Cell Host Microbe 8: 236-247.
21. Murphy KM, Stockinger B. (2010). Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 11: 674-680.
22. Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, Wendtner CM. (2009). Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 33: 460-464.
23. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C et al. (2007). CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 117: 3922-3929. (Pubitemid 350224101)
24. Quintanilla M, Brown K, Ramsden M, Balmain A. (1986). Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322: 78-80. (Pubitemid 16061512)
25. Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL et al. (2010). Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 16: 1662-1672.
26. Rijkers ESK, De Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. (2008). The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 45: 1126-1135. (Pubitemid 350016325)
27. Rosenblum MD, Olasz EB, Yancey KB, Woodliff JE, Lazarova Z, Gerber KA et al. (2004). Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Investig Dermatol 123: 880-887. (Pubitemid 39391933)
28. Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR et al. (2010). Reprogrammed Foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity 33: 942-954.
29. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P et al. (2009). Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111.
30. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. (2008). Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 57: 987-996.
31. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L et al. (2008). A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 9: 1074-1083.
32. Taylor N, McConachie K, Calder C, Dawson R, Dick A, Sedgwick JD et al. (2005). Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge. J Immunol 174: 143-154. (Pubitemid 40007400)
33. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. (2007). CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21: 566-568.
34. Tsitoura DC, DeKruyff RH, Lamb JR, Umetsu DT. (1999). Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol 163: 2592-2600. (Pubitemid 29399182)
35. Unger WW, Hauet-Broere F, Jansen W, van Berkel LA, Kraal G, Samsom JN. (2003a). Early events in peripheral regulatory T cell induction via the nasal mucosa. J Immunol 171: 4592-4603. (Pubitemid 37310575)
36. Unger WW, Jansen W, Wolvers DA, van Halteren AG, Kraal G, Samsom JN. (2003b). Nasal tolerance induces antigen-specific CD4+. Int Immunol 15: 731-739.
37. van der Marel AP, Samsom JN, Greuter M, van Berkel LA, O'Toole T, Kraal G et al. (2007). Blockade of IDO inhibits nasal tolerance induction. J Immunol 179: 894-900.
38. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. (2010). IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70: 10112-10120.
39. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G et al. (2011). Th17 cells in cancer: help or hindrance? Carcinogenesis 32: 643-649.
40. Wolvers DA, van der Cammen MJ, Kraal G. (1997). Mucosal tolerance is associated with, but independent of, up-regulation Th2 responses. Immunology 92: 328-333. (Pubitemid 27488143)
41. Wong KK, Khatri I, Shaha S, Spaner DE, Gorczynski RM. (2010). The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 88: 361-372.
42. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. (2001). The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102: 173-179. (Pubitemid 32217509)
43. Xu L, Kitani A, Fuss I, Strober W. (2007). Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 178: 6725-6729. (Pubitemid 46847395)
44. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD et al. (2008). TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453: 236-240. (Pubitemid 351667978)